Seeking Alpha

Neoprobe (NEOP -10.2%) fell sharply in afternoon trading on rumors an application for its...

Neoprobe (NEOP -10.2%) fell sharply in afternoon trading on rumors an application for its Lymphoseek cancer-detection drug was rejected. However, shares are up 5.8% AH after a spokesperson says Neoprobe isn't aware of any news about its application, which the FDA is expected to decide upon by Oct. 24.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs